Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy
Immunity, Inflammation and Disease · 2026-05 · 14 (5)
DOI: 10.1002/iid3.70402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 06.05.2026. Verfasst von Chunxia Feng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Oncology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China. Hauptthemen laut MEDLINE: Neoplasms, Biomarkers, Tumor, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suzhou Science and Technology Plan Project, Science and Technology Project of Suzhou Municipal Health Commission, Kunshan Science and Technology Plan Project.
Abstract (Originalsprache)
Objective
PD‐1 inhibitors are increasingly used in advanced cancers, but reliable biomarkers for predicting treatment response remain limited.
Methods
In this retrospective cohort study, we analyzed 335 patients with stage IV cancers treated with anti‐PD‐1 therapy (The First People's Hospital of Kunshan, 2019–2025). A predictive model integrating peripheral blood markers and clinical factors was developed using logistic and Cox regression.
Results
Histologic subtype, dNLR ≤ 3.18, AMC ≤ 0.48, and IL‐6 ≤ 12.35 were independent prognostic factors for OS and PFS (multivariate HRs reported). Patients with ≥ 3 favorable factors had significantly better outcomes. The model showed high accuracy for 1‐year survival prediction (AUC = 0.83) but limited performance beyond 3 years.
Conclusion
This study proposes a clinically feasible biomarker‐based tool to stratify PD‐1 inhibitor responders, though further validation in prospective cohorts is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy and Oncology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China.
- Department of Clinical Laboratory, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China.
ORCID-Profile: Ping Li
Förderung
- Suzhou Science and Technology Plan Project
- Science and Technology Project of Suzhou Municipal Health Commission
- Kunshan Science and Technology Plan Project
Zitieren
APA
Feng, C., Li, P., Gu, Q., Chen, M., & Gu, J. (2026). Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy. Immunity, Inflammation and Disease, 14(5). https://doi.org/10.1002/iid3.70402
Vancouver
Feng C, Li P, Gu Q, Chen M, Gu J. Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy. Immunity, Inflammation and Disease. 2026;14(5). doi:10.1002/iid3.70402
BibTeX
@article{Feng2026,
author = {Feng, Chunxia and Li, Ping and Gu, Qianhui and Chen, Minbin and Gu, Jinhua},
title = {Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {5},
doi = {10.1002/iid3.70402}
}
EUVIMED